What is lipodystrophy and how is it diagnosed?

What is Lipodystrophy?

Lipodystrophy is a heterogeneous group of rare disorders characterized by selective loss of subcutaneous adipose tissue (ranging from localized to partial to generalized), which leads to severe metabolic complications including insulin resistance, diabetes mellitus, hypertriglyceridemia, hepatic steatosis, and increased cardiovascular risk. 1, 2

Classification

Lipodystrophy is classified by two key features:

By Etiology

• Genetic (inherited): Can be autosomal recessive or dominant, manifesting at birth or later in childhood/puberty 1, 2
• Acquired: Develops secondary to HIV infection/antiretroviral therapy, autoimmune processes, or other triggers 1, 3

By Distribution of Fat Loss

• Generalized: Nearly complete absence of subcutaneous adipose tissue throughout the body 1, 2
• Partial: Selective fat loss from specific regions (extremities, face, trunk) with relative sparing of other areas 1, 2
• Localized: Limited fat loss in specific areas, typically without metabolic complications 4

Key Pathophysiologic Features

The loss of normal adipose tissue storage capacity results in:

• Ectopic fat deposition in skeletal muscle, liver, and myocardium causing lipotoxicity and insulin resistance 1
• Decreased leptin levels due to reduced adipose tissue mass 2, 5
• Impaired triglyceride clearance from circulation with delayed clearance of triglyceride-rich lipoproteins 1
• Increased hepatic lipid synthesis contributing to severe hypertriglyceridemia 1

Clinical Manifestations

Metabolic Complications (Partial and Generalized Forms)

• Insulin resistance progressing to type 2 diabetes mellitus 4, 6
• Severe hypertriglyceridemia (often 200-500+ mg/dL) with risk of eruptive xanthomas and acute pancreatitis 1, 7, 4
• Low HDL cholesterol 1, 4
• Non-alcoholic fatty liver disease (hepatic steatosis) 1, 4, 6
• Acanthosis nigricans 4, 6
• Polycystic ovarian syndrome in women, often with hirsutism 4, 6
• Hypertension 4

HIV-Associated Lipodystrophy (Most Common Acquired Form)

HIV-associated lipodystrophy presents in three patterns 3:

1. Lipoatrophy: Generalized or localized fat wasting, typically affecting face, extremities, and buttocks 1
2. Lipohypertrophy: Fat accumulation in abdomen, dorsocervical fat pad (buffalo hump), and breasts 1, 3
3. Mixed pattern: Central adiposity with peripheral lipoatrophy 3

Risk factors include increased duration of HIV infection, high viral load, low CD4 counts before HAART, and protease inhibitor exposure 3. Prevalence estimates range from 25-75% depending on diagnostic criteria used 1.

Severe Genetic Forms

Congenital generalized lipodystrophy is among the most severe forms, presenting at birth with nearly complete absence of subcutaneous fat and severe metabolic derangements including hypertriglyceridemia with eruptive xanthomas and pancreatitis risk 1.

Familial partial lipodystrophy (Dunnigan variety) involves fat loss predominantly from extremities, with hypertriglyceridemia more severe in women than men 1.

---

How to Diagnose Lipodystrophy

Diagnosis is primarily clinical, based on physical examination findings of selective fat loss, supported by body composition analysis and assessment of characteristic metabolic complications; genetic testing confirms diagnosis in suspected inherited forms. 2, 6

Step 1: Clinical Recognition - Physical Examination

Key Physical Findings to Identify

Look for selective loss of subcutaneous fat in characteristic distributions 2, 6:

• Face: Loss of buccal fat pads, prominent facial musculature, sunken cheeks 6
• Extremities: Loss of subcutaneous fat from arms and legs with prominent veins and muscular appearance 1, 6
• Trunk: Variable involvement depending on subtype 2
• Buttocks: Fat loss in lipoatrophic forms 1

Identify paradoxical fat accumulation (in acquired/HIV-associated forms) 1, 3:

• Dorsocervical fat pad (buffalo hump)
• Abdominal/visceral fat accumulation
• Breast hypertrophy in both men and women

Examine for associated metabolic stigmata 4, 6:

• Acanthosis nigricans (hyperpigmented, velvety skin in body folds)
• Eruptive xanthomas (yellow papules with erythematous bases on buttocks, shoulders, extensor surfaces) 7
• Hepatomegaly (from fatty liver)
• Signs of hirsutism or virilization in women

High-Suspicion Clinical Scenarios

Suspect lipodystrophy in lean, muscular patients presenting with 6:

• Diabetes mellitus (especially if young, non-obese, or treatment-resistant)
• Severe hypertriglyceridemia (>500 mg/dL)
• Non-alcoholic fatty liver disease without obesity
• Polycystic ovarian syndrome or amenorrhea
• Recurrent pancreatitis with elevated triglycerides

Step 2: Obtain Targeted History

Essential Historical Elements

• Family history: Autosomal patterns suggest genetic lipodystrophy 2
• Age of onset: Congenital vs. childhood vs. adult onset helps narrow differential 1, 2
• HIV status and antiretroviral medication history: Critical for identifying acquired HIV-associated lipodystrophy 1, 3
• Medication review: Protease inhibitors, NRTIs (especially stavudine), and other drugs associated with lipodystrophy 1
• Autoimmune history: Acquired generalized and partial lipodystrophy often have autoimmune etiology 2, 6
• Symptoms of metabolic complications: Polyuria, polydipsia, polyphagia (hyperglycemia); recurrent abdominal pain (pancreatitis risk) 7

Step 3: Laboratory Assessment

Initial Metabolic Screening

Obtain fasting lipid panel 1, 4:

• Triglycerides (often 200-500+ mg/dL, can exceed 1000 mg/dL in severe cases)
• HDL cholesterol (typically low)
• LDL cholesterol
• Total cholesterol

Assess glucose metabolism 4, 6:

• Fasting glucose
• Hemoglobin A1c
• Consider oral glucose tolerance test if initial screening normal but high suspicion

Evaluate hepatic involvement 4, 6:

• Liver function tests (AST, ALT)
• Consider hepatic imaging (ultrasound or MRI) for steatosis assessment

Measure leptin levels: Typically low or undetectable in generalized lipodystrophy, may be normal or low in partial forms 2, 5

Additional Metabolic Markers

• Insulin levels (assess insulin resistance)
• Renal function
• Uric acid
• In women: testosterone, DHEA-S, LH/FSH (evaluate for PCOS) 4, 6

Step 4: Body Composition Analysis

Quantify fat distribution using objective measures 2, 6:

• Dual-energy X-ray absorptiometry (DEXA): Provides regional and total body fat assessment
• Whole-body MRI: Gold standard for detailed fat distribution mapping 6
• Skinfold thickness measurements: Simple bedside assessment 6

These studies help distinguish lipodystrophy from simple leanness and characterize the pattern and extent of fat loss 2, 6.

Step 5: Genetic Testing (When Indicated)

Obtain genetic testing for suspected inherited lipodystrophy 2, 6:

• Confirms diagnosis in the proband
• Enables cascade screening of at-risk family members
• Multiple genes associated with different subtypes have been identified 1, 2
• Particularly valuable in children and young adults with metabolic complications

Step 6: Ophthalmologic Examination (If Severe Hypertriglyceridemia)

Perform fundoscopic examination when triglycerides are markedly elevated 7:

• Lipemia retinalis (creamy, milky appearance of retinal vessels) is pathognomonic for severe chylomicronemia and resolves with lipid-lowering therapy

Diagnostic Algorithm Summary

1. Physical examination reveals selective fat loss ± paradoxical fat accumulation
2. Metabolic screening demonstrates characteristic pattern: hypertriglyceridemia, low HDL, insulin resistance/diabetes, hepatic steatosis
3. Body composition analysis quantifies and maps fat distribution
4. Genetic testing confirms inherited forms
5. HIV/medication history identifies acquired forms

Common Diagnostic Pitfalls

Misdiagnosis as metabolic syndrome: The metabolic complications overlap significantly, but lipodystrophy patients are typically lean and muscular rather than obese 4. The key distinguishing feature is the visible loss of subcutaneous fat on examination.

Overlooking partial lipodystrophy: Subtle fat loss patterns may be missed, especially in partial forms where some fat depots are preserved 2. Systematic examination of all body regions is essential.

Failure to recognize HIV-associated lipodystrophy: The absence of a standardized case definition has led to variable recognition 1. Always assess fat distribution in HIV patients on antiretroviral therapy, particularly those on protease inhibitors or long-term NRTI exposure.

Delaying diagnosis until severe complications develop: Lipodystrophy is progressive, and complications are potentially life-threatening 2. Early recognition enables preventive interventions before irreversible metabolic damage occurs.